Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 28–Jul 5, 2026)

Here’s what’s on the biotech calendar for June 28–July 5: 2 FDA decision dates, 15 trial catalysts, and 0 earnings reports from tracked companies.

💊 FDA Decisions (PDUFA Dates)

🧪 Trial Catalysts & Milestones

• OSTX — 2026-06-30: Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metas
• ADCT — 2026-06-30: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Ca
• ARV — 2026-06-30: Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil,
• OSTX — 2026-06-30: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Ca
• SIGN — 2026-06-30: Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to C
• SIGN — 2026-06-30: A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
• CMPS — 2026-06-30: The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Di
• OSTX — 2026-06-30: A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in
• OSTX — 2026-06-30: Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy T
• OSTX — 2026-06-30: Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refrac
• OSTX — 2026-06-30: Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreat
• ARV — 2026-06-30: Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [AD
• ARV — 2026-06-30: A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Be
• OSTX — 2026-06-30: A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI
• OSTX — 2026-06-30: Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mut

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

• CELC — NDA in 19 days, score 79/100
• VERA — BLA in 9 days, score 79/100
• UNCY — NDA in 1 days, score 79/100

📈 Last Week’s Biggest Gainers

• APGE +46.66% (volume 32.0x average)
• DPC +42.06% (volume 60158.7x average)
• SNDK +21.53% (volume 1.0x average)
• TECH +20.08% (volume 18.8x average)
• BB +19.95% (volume 2.4x average)

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.